Nootropic Research Market

Semax

A synthetic neuropeptide analog often discussed for cognitive and neuroprotection-related interest in research-market circles.

NootropicNeuropeptideCognition

Also appears in: Immune

Price compare
90 tracked offers across 90 vendors · 15 dosages
Best trust-adjusted value: Peptide Partners · Strong trust · $1.03/mg
From
$1.03/mg
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Category
Nootropic

Primary lane: Nootropic. Also surfaces under Immune for browsing and discovery.

Aliases
0

No major aliases are tracked for this profile yet.

Signal depth
Low

No FDA label signal · 0 trials · 399 PubMed results

Preclinical
Research evidence

Current evidence for Semax is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.

Semax has no clinical trials that name it and 399 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.

Human data
Lab / animal only
Trial quality
No human trials
Outcomes
No human trials
Replication
Multiple papers
Literature
High-impact
The Journal of Clinical Endocrinology & Metabolism · 94 citations MSH/ACTH 4-10 Influences Behavioral and Physiological Measures of Attention<sup>1</sup> Psychopharmacology · 62 citations Some effects of ACTH 4-10 on performance during a serial reaction task Psychopharmacology · 59 citations ACTH 4-10 in the amelioration of neuropsychological symptomatology associated with senile organic brain syndrome English Abstract [Effect of a combined physiotherapeutic approach on changes in functional parameters after endovitreal surgery of rhegmatogenous retinal detachment with a favorable anatomical outcome]. Journal Article Multi-Layer Magnetic Shields Based on Fe-Based Nanocrystalline and Co-Based Amorphous Ribbons. Journal Article Digitally Guided Hybrid Maxillary Expansion with Supragingival Mandibular Miniplates for Class III Correction in Late Adolescents: A Pilot Clinical Study.
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What semax is

Semax is a synthetic neuropeptide analog that appears in nootropic and neuroprotection conversations. It is often grouped near selank, but the two should not be treated as interchangeable.

Why it matters

This profile helps build out the cognitive side of the peptide library and makes the nootropic category feel intentional instead of token.

Regulatory context

Semax is not an FDA-approved cognitive or neurologic peptide medicine in the United States. It belongs to the research-market/nootropic side of peptide discussion.

Practical reading note

Readers should expect wide variation in claim quality here. Mechanistic interest and community demand do not automatically translate into strong clinical evidence.